{
  "id": 15045552,
  "title": "Paul Mahon, United Therapeutics EVP, sells $4.5m in stock",
  "url": "https://urgent.news/2026/10/16/paul-mahon-united-therapeutics-evp-sells-4-5m-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-16T21:01:06.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/paul-mahon-united-therapeutics-evp-sells-45m-in-stock-93CH-4954856"
  },
  "original_language": "en",
  "account": "Paul A. Mahon, the Executive Vice President and General Counsel at United Therapeutics Corp (NASDAQ: UTHR), exercised stock options and sold 8,300 shares of the company's common stock on October 15, 2026. The sale generated approximately $4.5 million, with shares traded at prices between $541.015 and $547.06. The biotech firm, with a market capitalization of $22.84 billion, posted a 25% return over the past year, but analyst reports suggest the stock is trading above its Fair Value. Before selling, Mahon acquired the same number of shares through stock option exercise, spending $1.21 million. Both the option exercise and share sales were executed under a pre-arranged 10b5-1 trading plan, which Mahon established on August 11, 2025. After these transactions, Mahon directly holds 45,172 shares of UTHR common stock and maintains 30,940 derivative securities in the form of stock options. United Therapeutics' balance sheet shows more cash than debt, according to InvestingPro's financial health score.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "MapLight Therapeutics chief scientific officer sells $93,025 in shares",
        "url": "https://urgent.news/2026/10/16/maplight-therapeutics-chief-scientific-officer-sells-93-025-in-shares",
        "published": "2026-10-16T21:31:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}